Advertisement
YOU ARE HERE: LAT HomeCollectionsStrattera Drug
IN THE NEWS

Strattera Drug

FEATURED ARTICLES
BUSINESS
August 15, 2002 | Bloomberg News and Reuters
Eli Lilly & Co. said regulators may require a new trial for its experimental treatment for attention deficit hyperactivity disorder, a drug Wall Street has been counting on to win approval and become a big seller. A Lilly spokesman said the Food and Drug Administration has deemed the drug, called Strattera, "approvable." But he said final approval was contingent on the firm providing the FDA additional clinical trial data or analyses that might require a new trial.
ARTICLES BY DATE
BUSINESS
August 15, 2002 | Bloomberg News and Reuters
Eli Lilly & Co. said regulators may require a new trial for its experimental treatment for attention deficit hyperactivity disorder, a drug Wall Street has been counting on to win approval and become a big seller. A Lilly spokesman said the Food and Drug Administration has deemed the drug, called Strattera, "approvable." But he said final approval was contingent on the firm providing the FDA additional clinical trial data or analyses that might require a new trial.
Advertisement
NATIONAL
December 18, 2004 | From Associated Press
Strattera, a drug used to treat attention-deficit (hyperactivity) disorder, is getting an updated warning label to highlight the risk that it might contribute to severe liver problems in some patients, the government said Friday. The new warning says the medication should be discontinued in patients who develop jaundice or show laboratory evidence of liver injury.
CALIFORNIA | LOCAL
March 17, 2006 | Roy Rivenburg, Times Staff Writer
A psychiatric patient who hanged himself at UCI Medical Center in December was treated with an unapproved drug known to increase suicidal thoughts and was not monitored properly, state health regulators said Thursday. The report from the Department of Health Services criticized the patient's UCI doctor, nurses and pharmacists.
CALIFORNIA | LOCAL
April 7, 2006 | Christian Berthelsen, Times Staff Writer
UCI Medical Center has told state health regulators it will require pharmacists to review and approve physicians' unconventional use of drugs to treat patients, as part of a plan to correct deficiencies discovered in the wake of a patient suicide in December.
Los Angeles Times Articles
|